Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

WARREN, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), is proud to recognize Curtis Patton, PhD, founding member of Tevogen’s Board of Directors and Professor Emeritus at Yale University, as he is honored in a new joint portrait commissioned by the Yale School of Medicine’s Program for Art in Public Spaces.

The portrait celebrates the extraordinary, decades-long contributions of Dr. Patton and James Comer, MD, MPH, Maurice Falk Professor in the Child Study Center, whose work has shaped generations of medical students, residents, fellows, and early-career faculty through their unwavering commitment to mentorship, community building, and public health leadership.

Dr. Patton’s effort across academic, public and private verticals have had a lasting impact on Tevogen, particularly as the Company continues to advance its ExacTcell precision T cell platform, scale Tevogen.AI’s predictive technologies, and execute on its growth initiatives, all with the ultimate goal of improving patient outcomes while achieving commercial success, including revenue forecasts exceeding $1 billion.

The portrait, created by artist Mario Moore (MFA ’13), will be unveiled on Thursday, December 11, 2025 at 4 p.m. in the Harvey Cushing/John Hay Whitney Medical Library at Yale School of Medicine.

“Dr. Patton’s leadership and scientific vision have played a pivotal role in shaping Tevogen’s foundation,” said Dr. Ryan Saadi, Founder & CEO of Tevogen. “His legacy at Yale reinforces the strength of the Company’s mission during a period of significant momentum.”

“Dr. Patton’s brilliance is matched only by his humanity. His lifelong commitment to public health and mentorship has elevated the field and all of us fortunate enough to work with him,” commented Susan M. Podlogar, of Tevogen’s board of directors.

Tevogen Bio extends its heartfelt congratulations to Dr. Patton on this well-deserved recognition.

About Tevogen

Tevogen is a next-generation, socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages industry-leading artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and strategic engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.